Related Experiment Video
Updated: Aug 5, 2026

Analysis of Fucosylated Human Milk Trisaccharides in Biotechnological Context Using Genetically Encoded Biosensors
Published on: April 13, 2019
Sustainable production of recombinant FGF2 in cell culture spent media using engineered Lactococcus lactis: Modelling
Prashant Mainali1, Jin Hao Tan1, Jun Ping Quek1
1Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A⁎STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Republic of Singapore.
Abstract:
Spent mammalian cell culture media are commonly discarded despite having residual nutrients that could be repurposed for microbial biomanufacturing. Fibroblast growth factor 2 (FGF2) is a major cost contributor in serum-free cell culture media, motivating the development of economical production strategies. Here, we investigated the use of fortified spent cell culture media for FGF2 production using Lactococcus lactis, a GRAS microorganism, and integrated statistical optimization, kinetic modeling, and continuous bioprocessing. A Box-Behnken design identified 10 g/L glucose, 35 °C cultivation temperature, and 100 ng/mL nisin as optimal conditions for enhancing intracellular and secreted FGF2 production. Subsequently, kinetic model comprising of ordinary differential equations was developed to describe temporal profiles of intracellular & secreted FGF2, glucose, lactate, and biomass. The model integrated Monod-type kinetics for growth and substrate consumption, and Luedeking-Piret kinetics to account for FGF2 production. Leveraging this model, we demonstrated that model could guide selection of dilution rate to maximize FGF2 production. To advance toward continuous manufacturing, chemostat cultivation was coupled with depth and crossflow filtration to enable real-time cell separation and FGF2 concentration. The concentrated FGF2 demonstrated comparable bioactivity to commercial FGF2 in proliferating Anguilla japonica (Japanese eel) pre-adipocytic cells. Overall, our study demonstrated utilization of design of experiments (DoE) alongside kinetic modelling to optimize bioprocess conditions, achieving FGF2 production of 16 mg/L and 396 µg/L titres for intracellular and secreted forms, respectively. The circular bioprocess, use of predictive modelling and integration of continuous upstream-downstream operation provides an opportunity for growth factor manufacturing from L. lactis.
Related Concept Videos
Upstream Processing
Bioreactor Controls-III
Scale-Up Processes
Production of Pharmaceuticals
